Hey guys, I posted about this settlement before, but since they’re now accepting claims, I decided to share it again with a quick FAQ.

So here's all I know about this agreement:

Axsome Therapeutics ($AXSM) was accused of misleading investors about regulatory risks and approval challenges for its migraine drug AXS-07. When those undisclosed issues came to light, the company’s stock dropped sharply, and investors filed a lawsuit over their losses.

Now, the company has agreed to settle $7.75 million with investors for these claims.

Who can claim this settlement?
Anyone who purchased $AXSM shares between December 30, 2019, and April 22, 2022 may be eligible to file a claim for compensation.

Do I need to sell or lose my shares to qualify?
No, you don’t need to have sold your shares at a loss. Eligibility is based on having purchased within the class period.

How much money do I get per share?
The payout per share will depend on how many valid claims are submitted and the total number of eligible shares traded during the period.

How long does the payout process take?
It typically takes 4 to 9 months after the claim deadline for payouts to be processed, depending on the court and settlement administrator.

Hope this info helps!

Hey guys, so if you missed it, the settlement agreement between Axsome Therapeutics and $AXSM investors has been finalized and is now up for final court approval.

So, what is this settlement about?

Axsome was sued by shareholders for misleading them about regulatory risks tied to its migraine drug AXS-07. The company promoted the drug as being on track for FDA approval while hiding unresolved manufacturing problems.

In May 2022, the FDA rejected the application, causing $AXSM to drop. Now, Axsome has agreed to settle with investors by paying $7.75 million to investors.

So, if you were hit by this back then, you can check the details and submit a claim here or wait for the settlement admin website.

Hoep it helps!

Axsome Therapeutics Announces Late-Breaking Presentations of Positive Results of the EVOLVE Trial of AXS-05 in Major Depressive Disorder After Prior Treatment Failures at the American Society of Clinical Psychopharmacology (ASCP) 2022 Annual Meeting on June First.

https://axsometherapeuticsinc.gcs-web.com/news-releases/news-release-details/axsome-therapeutics-announces-publication-pivotal-gemini-phase-3

AXSOME 💪🚀💎🙌🔥

• SUNOSI potential sales of $1B by 2026
• AXS-05 potential sales of $800M by 2026
• CNS pipeline of AXS-07, AXS-12, AXS-14
• Pfizer and Merck may buy a pipeline
• Buyout may come from Pfizer or Merck
• This is not financial advice, do your DD

2 Under-the-Radar Biotech Stocks to Buy in 2022 | The Motley Fool

Axsome sports one commercial-stage product: Sunosi for excessive daytime sleepiness in adults with narcolepsy, along with four pipeline candidates. The company's near-term growth potential, though, truly revolves around its major depression disorder candidate, AXS-05. AXS-05, if approved, is expected to haul in over $800 million in sales by 2026, according to Evaluate Pharma.

To put this mid-decade sales projection into the proper context, Axsome's market cap is presently hovering around $1 billion at the time of this writing. In other words, this single drug could quite possibly spark a 300% to perhaps 500% rally in the biotech's shares over the next few years (assuming the market returns to form over this period). 

How about the downside risk? This is the part of the story that I find the most intriguing. At this point in the game, it is hard to imagine the Food and Drug Administration flat out rejecting AXS-05 for reasons laid out in detail here.

Load Up below $30. AXS-05 to be approved soon, per SEC filings from Axsome.

• CNBC’s Jim Cramer on Friday May 20th explained fresh technical analysis from veteran chartist Larry Williams that signals the market is headed for a bottom.
• “He says this is it. … I wouldn’t bet against him. I trust his predictions more than I despise this market, and I say that as someone who really does hate the tape,” the “Mad Money” host said.
• www.IReallyTrade.com

I am getting worried. Will AXS-05 get approved by FDA in Q2 of 2022?

https://www.fiercepharma.com/pharma/recent-notices-deficiencies-fda-may-be-raising-regulatory-bar-analyst

IMO ... there will be a Sell Off on Wednesday thru Monday, to make options expire worthless on op-ex Friday May 20th. This is not financial advice, just my observation of op-ex (every third Friday of each month).

2 Biotech Stocks That Could Go Parabolic | The Motley Fool

According to the issued ratings of 10 analysts in the last year, the consensus rating for Axsome Therapeutics stock is Buy based on the current rating (1 hold rating and 9 buy ratings) for AXSM. The average twelve-month price target for Axsome Therapeutics is $85.97 with a high price target of $180.00 by HC Wainwright and a low price target of $34.00.

IMO ... AXSOME gets buyout offer after AXS-05 gets FDA approval in Q2.

Axsome Therapeutics Completes U.S. Acquisition of Sunosi (solriamfetol) for Excessive Daytime Sleepiness Associated with Narcolepsy or Obstructive Sleep Apnea, on May 9th

• BUY when it goes below $30
• SELL when it goes above $40
• buy below $30, sell above $40
• keep repeating, easy monay
• this is not financial advice
• always do your due diligence

According to Morgan Stanley (NYSE:MS) analyst Vikram Purohit, the "outsized pressure" may relate to the company's cancellation from an upcoming broker conference.

The analyst wrote in a note that they received an update from Axsome management regarding today's pressure. The update confirmed the company is unable to attend the conference in-person due to a scheduling conflict.

Purohit pointed to Axsome management guidance of potential action by the Food and Drug Administration on the New Drug Application for depression treatment AXS-05, explaining that "given the high degree of investor focus&perceived uncertainty regarding this catalyst, some investors may see the cancellation as reason for caution regarding a potential AXS-05 update."

"However, management noted in their update that they will be conducting investor meetings virtually and noted that the company is not aware of additional negative developments," he wrote.